SEC Form 4	
------------	--

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-0287	
	Estimated average burden		
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934	hours per response:	0.5	
or Section 30(h) of the Investment Company Act of 1940			

I

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	Filed pursu	PF CHANGE ant to Section 16(a) ection 30(h) of the I	of the S	Securit	ties Exchange	Act of 1	_	Estin	Number: nated average burg s per response:	3235-0287 den 0.5
1. Name and Address of Reporting Person <sup>*</sup> Iannone Robert		2. Issuer Name and Ticker or Trading Symbol Jazz Pharmaceuticals plc [ JAZZ ]						ationship of Report ( all applicable) Director Officer (give title	10% C Other	Owner (specify
(Last) (First) (Middle) 5TH FL, WATERLOO EXCHANGE WATERLOO RD		ate of Earliest Trans 09/2022	saction (	Month	n/Day/Year)		below) EVP, Global	below Head of R&I	,	
(Street) DUBLIN 4 L2	4. lf	4. If Amendment, Date of Original Filed (Month/Day/Year)						vidual or Joint/Grou Form filed by Or Form filed by Mo Person	e Reporting Per	son
(City) (State) (Zip)										
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1. Title of Security (Instr. 3) Date (Month/Da		Execution Date,		iction Instr.	/ //) ar			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	12/09/2022		Code S		1,844	(D) D	\$151.54	(Instr. 3 and 4) 36,316 <sup>(1)</sup>	D	

orunnary	onares		12/09/2						1,011		<b>Ψ101</b>		,510	D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned   (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Deriv Secu Acqu (A) o Dispe	Number 6. Date Exercisable and Expiration Date (Month/Day/Year) ; guired ) or sposed (D) str. 3, 4				8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Includes 51 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2022.

<u>By: /s/Adam Guttmann, as</u>	
attorney in fact For: Robert	12/13/2022
Iannone	

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.